Pharmacogenetic Aspects of Type 2 Diabetes Treatment

Pharmacogenetic Aspects of Type 2 Diabetes Treatment

In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy. T allele of the KCNJ11 rs2285676 gene polymorphism and G allele of KCNJ11 rs5218 gene polymorphism are assoc...

Full description

Bibliographic Details
Main Authors:	N. O. Pozdnyakov, I. N. Kagarmanyan, A. E. Miroshnikov, E. S. Emelyanov, A. A. Gruzdeva, A. M. Sirotkina, I. A. Dukhanina, A. A. Milkina, A. A. Khokhlov, S. O. Pozdnyakov
Format:	Article
Language:	Russian
Published:	Scientific Сentre for Family Health and Human Reproduction Problems 2020-07-01
Series:	Acta Biomedica Scientifica
Subjects:	diabetes mellitus pharmacogenetics kcnj11 tcf7l2 slc22a1 slc22a3 cyp2c9 cyp2c8 pparγ
Online Access:	https://www.actabiomedica.ru/jour/article/view/2362

Similar Items

PHARMACOGENETICS OF ORGANIC CATION TRANSPORTERS
by: V. A. Evteev, et al.
Published: (2018-06-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
by: M I Savelyeva, et al.
Published: (2017-06-01)

Pharmacogenetic Tests in the Nephrological Clinic
by: D.D. Ivanov, et al.
Published: (2016-10-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Dual actions on gout flare and acute kidney injury along with enhanced renal transporter activities by Yokuininto, a Kampo medicine
by: Seung Hoon Lee, et al.
Published: (2019-03-01)

PREVALENCE OF POLYMORPHOUS LOCUS 681G>A OF CYP2C19 GENE IN RUSSIAN POPULATION
by: T. A. Bairova, et al.
Published: (2014-11-01)

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
by: Jeiziner C, et al.
Published: (2021-02-01)

Pharmacogenetic Warfarin Dosing Algorithm in the Russian Population
by: T. A. Bairova, et al.
Published: (2019-07-01)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
by: Ron H. N. van Schaik, et al.
Published: (2020-09-01)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
by: Nita A Limdi, et al.
Published: (2012-10-01)

Use of Pharmacogenetic Drugs by the Dutch Population
by: Mohammad A. Alshabeeb, et al.
Published: (2019-07-01)

Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
by: Arzu Gunes, et al.
Published: (2010-03-01)

GENETIC POLYMORPHISM OF CYTOCHROMES P450 2C9 AND 2C19 IN SLOVENIAN POPULATION
by: Darja Herman, et al.
Published: (2003-06-01)

The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study
by: Rafał Świechowski, et al.
Published: (2021-10-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
by: Nizamuddin S, et al.
Published: (2021-01-01)

<i>Drosophila</i> SLC22 Orthologs Related to OATs, OCTs, and OCTNs Regulate Development and Responsiveness to Oxidative Stress
by: Darcy C. Engelhart, et al.
Published: (2020-03-01)

Pharmacogénétique et pharmacogénomique des inhibiteurs de tyrosine kinases : exemple de la leucémie myéloide chronique
by: Dulucq, Stéphanie
Published: (2012)

Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects
by: Dorofeeva MN, et al.
Published: (2019-11-01)

Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications
by: Marin Veldic, et al.
Published: (2019-02-01)

Polymorphisms of ABCG2 and SLC22A12 Genes Associated with Gout Risk in Vietnamese Population
by: Nguyen Thuy Duong, et al.
Published: (2019-01-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
by: D. A. Sychev, et al.
Published: (2015-12-01)

Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs
by: Tyler C. Beck, et al.
Published: (2021-05-01)

Downregulation of organic cation transporters OCT1 (<it>SLC22A1</it>) and OCT3 (<it>SLC22A3</it>) in human hepatocellular carcinoma and their prognostic significance
by: Heise Michael, et al.
Published: (2012-03-01)

Amplicon targeted resequencing for SLC2A9 and SLC22A12 identified novel mutations in hypouricemia subjects
by: Zhaowei Zhou, et al.
Published: (2019-07-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Assessing CYP2C8-Mediated Pharmaceutical Excipient-Drug Interaction Potential: A Case Study of Tween 80 and Cremophor EL−35
by: Chengming Wen, et al.
Published: (2021-09-01)

Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
by: Ramón Cacabelos, et al.
Published: (2021-04-01)

Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants
by: J.A. Perini, et al.
Published: (2009-12-01)

Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus
by: Sabina Semiz, et al.
Published: (2010-11-01)

Pharmacogenetics of Major Depressive Disorder (MDD): Progress in Two Serotonergic Targets
by: Chidiebere Michael Iro, et al.
Published: (2018-11-01)

The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches
by: P. N. Vlasov, et al.
Published: (2017-06-01)

Expression von Aufnahme-Transportern für Zytostatika in Mamma- und Prostatakarzinom-Zellen und ihre Interaktion mit Zytostatika
by: Müller, Judith
Published: (2017)

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
by: Emaad Abdel-Kahaar, et al.
Published: (2019-09-01)

The pharmacogenetics antiepileptic drugs
by: N. A. Shnayder, et al.
Published: (2008-12-01)

Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
by: Ingrid Fricke-Galindo, et al.
Published: (2021-03-01)

PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS
by: A. L. Khokhlov, et al.
Published: (2018-02-01)